Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Ireland-based inflammatory disease drug developer Inflazome was acquired by pharmaceutical firm Roche today for €380m ($448m) in an upfront payment, providing an exit to pharmaceutical firm Novartis. Inflazome is eligible to receive additional milestone payments, but details were not revealed. Founded in 2016, Inflazome is working on drugs that target inflammasomes, which drive chronic inflammatory…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.